IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive: It is a little more than ten years ago that the first TKI, imatinib, was approved for the treatment of chronic myeloid leukemia (CML) patients who had failed prior therapy with interferon-α (IFN).